Tests on new NNRTI show strong potency.
Early clinical studies of TMC125, a new non-nucleoside reverse transcriptase inhibitor, indicate the drug is extremely potent, with an average reduction in HIV viral load of 99% after one week of treatment.
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009570:Nitriles; D010919:Placebos; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D009570:Nitriles; D010919:Placebos; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine